ksv01
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 7, 2025 (NCT07260812)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07246707 | Phase 1 | Nov 30, 2025 | TScan Therapeutics, Inc., Zhejiang University |
| NCT07260812 | Phase 1 | May 7, 2025 | Huazhong University of Science and Technology, TScan Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TScan Therapeutics, Inc. | For profit | 2 | 1 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1